Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10472517 | 0.97 | TDP1 (0.51) | TDP1ALOX5SMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL26830309 | 0.94 | LTA4H (0.49) | TDP1ALOX5SMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL3630884 | 0.88 | LTA4H (0.49) | TDP1ALOX5LTA4HALDH1A1CYP4F2 | |
| SCHEMBL2722347 | 0.88 | ALOX5 (0.53) | TDP1ALOX5SMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL23051792 | 0.88 | ALDH1A1 (0.53) | TDP1SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL19434617 | 0.88 | ALDH1A1 (0.46) | TDP1SMN1; SMN2LTA4HALDH1A1PPID | |
| SCHEMBL9212182 | 0.86 | ALOX5 (0.52) | TDP1ALOX5SMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL16672928 | 0.86 | TDP1 (0.54) | TDP1SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL21801168 | 0.86 | ALDH1A1 (0.47) | TDP1SMN1; SMN2LTA4HALDH1A1PPID | |
| SCHEMBL16673421 | 0.86 | TDP1 (0.59) | TDP1ALOX5SMN1; SMN2LTA4HPPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-8445525-B2 | Carboxylic acid amides, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-1771441-B8 | NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| EP-1771441-B1 | NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7947700-B2 | Factor Xa or related serine protease inhibitors; such as 3-chloro-N-[1-(5-chloro-1H-benzimidazol-2-yl)-ethyl]-4-(1,4-diazepan-1-yl)benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-20110077236-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20080146539-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-7371743-B2 | Carboxylic acid amides, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| EP-1771441-A1 | NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20050203078-A1 | Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| WO-2005082895-A1 | NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | TDP1 1550/4885ALOX5 1164/4885SMN1; SMN2 597/4885 |
| US-20080146539-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | OAT, ASS1, OTC | TDP1 3116/4885ALOX5 392/4885SMN1; SMN2 4292/4885 |
| US-20110077236-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | OAT, ASS1, OTC | TDP1 3116/4885ALOX5 392/4885SMN1; SMN2 4292/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | TDP1 1522/4885ALOX5 565/4885SMN1; SMN2 306/4885 |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | TDP1 4722/4885ALOX5 2686/4885SMN1; SMN2 2391/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | TDP1 1522/4885ALOX5 565/4885SMN1; SMN2 306/4885 |
| US-20050203078-A1 | Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide | F12, TFPI, F11 | TDP1 519/4885ALOX5 2111/4885SMN1; SMN2 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.